Literature DB >> 22870442

Viscosupplementation with hylan g-f 20 in patients with osteoarthrosis of the knee.

Jack M Bert1, David D Waddell.   

Abstract

Viscosupplementation (VIS) is one of several treatment modalities for osteoarthritis of the knee. It is useful in the treatment of osteoarthritis when other methods of conservative care have failed and it may be a safer method of treatment than oral chemical therapy which can have significant side effects with even short-term usage. The biochemical effects of hyaluronic acid are incompletely understood, however there are several accepted modes of action which result in a positive clinical effect on the function of the knee joint. There is some evidence that hyaluronic acid preparations with a higher molecular weight may be more beneficial to the patient. It is commonly used after arthroscopic meniscectomy and or debridement of the knee in a patient with chondral disease. The clinical effects have been well documented in multiple studies in patients with mild to moderate osteoarthritis in study groups before or after arthroscopic surgery of the knee. Adverse events do occur and are easily treated with only rare case reports of systemic effects. Furthermore, there is some evidence that VIS can prolong the need for total knee arthroplasty in the older patient as well.

Entities:  

Keywords:  knee osteoarthritis; postarthroscopy; viscosupplementation

Year:  2010        PMID: 22870442      PMCID: PMC3382675          DOI: 10.1177/1759720X10370930

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  44 in total

1.  Intra-articular hylan G-F 20 (Synvisc) in the management of patellofemoral osteoarthritis of the knee (POAK).

Authors:  Shane Clarke; Vanessa Lock; John Duddy; Mohammed Sharif; John H Newman; John R Kirwan
Journal:  Knee       Date:  2005-01       Impact factor: 2.199

2.  Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis.

Authors:  J P Raynauld; C H Goldsmith; N Bellamy; G W Torrance; R Polisson; D Belovich; D Pericak; P Tugwell
Journal:  Osteoarthritis Cartilage       Date:  2005-02       Impact factor: 6.576

3.  A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up.

Authors:  David D Waddell; Charles A Cefalu; DeWayne C Bricker
Journal:  J Knee Surg       Date:  2005-01       Impact factor: 2.757

4.  An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis.

Authors:  David D Waddell; Charles A Cefalu; DeWayne C Bricker
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

5.  The burden of musculoskeletal conditions at the start of the new millennium.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2003

6.  Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis.

Authors:  Grace H Lo; Michael LaValley; Timothy McAlindon; David T Felson
Journal:  JAMA       Date:  2003-12-17       Impact factor: 56.272

7.  A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee.

Authors:  David Caborn; Joel Rush; William Lanzer; Dennis Parenti; Christopher Murray
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

8.  Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials.

Authors:  Chen-Ti Wang; Jinn Lin; Chee-Jen Chang; Yu-Tsan Lin; Sheng-Mou Hou
Journal:  J Bone Joint Surg Am       Date:  2004-03       Impact factor: 5.284

9.  Increased intercellular communication through gap junctions may contribute to progression of osteoarthritis.

Authors:  Andrew A Marino; David D Waddell; Oleg V Kolomytkin; William D Meek; Robert Wolf; Kalia K Sadasivan; James A Albright
Journal:  Clin Orthop Relat Res       Date:  2004-05       Impact factor: 4.176

10.  Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis.

Authors:  André Kahan; Pierre-Louis Lleu; Laurence Salin
Journal:  Joint Bone Spine       Date:  2003-08       Impact factor: 4.929

View more
  4 in total

1.  Hyaluronan modulates TRPV1 channel opening, reducing peripheral nociceptor activity and pain.

Authors:  Rebeca Caires; Enoch Luis; Francisco J Taberner; Gregorio Fernandez-Ballester; Antonio Ferrer-Montiel; Endre A Balazs; Ana Gomis; Carlos Belmonte; Elvira de la Peña
Journal:  Nat Commun       Date:  2015-08-27       Impact factor: 14.919

2.  Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan.

Authors:  Aida Marcotti; Ana Miralles; Eduardo Dominguez; Eliseo Pascual; Ana Gomis; Carlos Belmonte; Elvira de la Peña
Journal:  Pain       Date:  2018-04       Impact factor: 7.926

3.  Evaluation of Hylan G-F 20 Treatment with Opioid Prescriptions and Intraarticular Corticosteroid Injections in Patients with Osteoarthritis of the Knee Using a Claims Database.

Authors:  Michael J Langworthy; Charles D Hummer; Wilson Ngai; Lichen Hao; David Webner
Journal:  Cartilage       Date:  2020-10-23       Impact factor: 4.634

4.  Effect of insulin-like growth factor-1 and hyaluronic acid in experimentally produced osteochondral defects in rats.

Authors:  Celil Alemdar; İstemi Yücel; Barış Erbil; Havva Erdem; Ramazan Atiç; Emin Özkul
Journal:  Indian J Orthop       Date:  2016 Jul-Aug       Impact factor: 1.251

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.